Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has been appointed as Chief Executive Officer of the Company.
Dr. Golumbeski brings to the team nearly twenty years of industry experience serving most recently as Vice President of Business Development, Licensing & Strategy for the oncology business unit at Novartis. In this position he was responsible for the full array of business development activities leading several transactions which have resulted in projects currently in Phase III studies. While at Novartis, Dr. Golumbeski also served as a member of the Executive Committee which oversees overall oncology business performance. Prior to his tenure at Novartis, he led transactions which have resulted in two products that have been approved or are in registration in the US and the EU.
“I am excited to join Nabriva at this important stage of its growth. The Company’s highly differentiated compounds have the potential to address the significant need for new classes of effective antibiotics. Furthermore, the team at Nabriva is highly experienced with a deep understanding and enthusiasm for the development of novel antibiotics” commented Dr. Golumbeski.
David Chiswell, Chair of the Supervisory Board, added “We are pleased to welcome George to the team. His leadership skills combined with his strategic and business development insight will help position Nabriva as one of the leading specialist companies in antibiotics development.”
About Nabriva Therapeutics:
Headquartered in Vienna, Nabriva Therapeutics is engaged in the discovery and development of innovative antibacterial agents addressing unmet medical need in the hospital and community setting. The company has two compounds currently in clinical trials and expects to have a third compound enter clinical trials later this year. The lead compound, BC-3205, is a parenterally and orally available pleuromutilin which is first in class and has significant market potential in multiple indications (eg. SSSI & CAP). All of Nabriva’s programs are derived from compounds generated in-house through discovery activity and the company maintains an ongoing effort in medicinal chemistry.
The Company was founded in January 2006 as a spin-out of Sandoz GmbH Kundl. The spin-out was led by Nomura Phase4 Ventures with a Series A financing of €42 million with a syndicate that included HBM Partners, GLSV, The Wellcome Trust and Novartis Venture Fund.
Source: www.nabriva.com